ImmuneOnco announced dosing of first patient in its recently initiated Phase 1b/2 clinical trial of IMM2510/SYN-2510 in combination with chemotherapy in patients with advanced NSCLC in China ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Rights Mar 22, 2024 Mar 22, 2024 Feb 14, 2024 Rights ratio: 28 share for every 10 held at a price of Rs 10.0 Rights Sep 03, 2023 Sep 22, 2023 Jun 30, 1993 Rights ratio: 1 share for every 7 held at a ...